Abstract
1 Daily treatment of two-kidney clipped renal hypertensive rats with hydrallazine, hydrochlorothiazide (HCTZ) and a new orally active inhibitor of the angiotensin-converting enzyme, captopril (SQ14,225), was correlated with survival rates for up to 9 months.
2 The groups of rats given captopril alone or captopril plus intermittent or chronic HCTZ had the best survival rate, whereas HCTZ alone or hydrallazine did not beneficially affect survival.
3 Survival rates correlated well with control of BP in these animals.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ferguson R. K., Turini G. A., Brunner H. R., Gavras H., McKinstry D. N. A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet. 1977 Apr 9;1(8015):775–778. doi: 10.1016/s0140-6736(77)92958-0. [DOI] [PubMed] [Google Scholar]
- Freis E. D., Ragan D., Pillsbury H., 3rd, Mathews M. Alteration of the course of hypertension in the spontaneously hypertensive rat. Circ Res. 1972 Jul;31(1):1–7. doi: 10.1161/01.res.31.1.1. [DOI] [PubMed] [Google Scholar]
- Leenen F. H., Ackerman E. W. Effects of propranolol on development and maintanance of severe renal hypertension in rats. Clin Exp Pharmacol Physiol. 1976 Nov-Dec;3(6):575–586. doi: 10.1111/j.1440-1681.1976.tb00639.x. [DOI] [PubMed] [Google Scholar]
- Lundgren Y. Blood pressure and vascular design in renal hypertension in rats after prolonged propranolol treatment. Acta Physiol Scand. 1974 Jul;91(3):409–416. doi: 10.1111/j.1748-1716.1974.tb05695.x. [DOI] [PubMed] [Google Scholar]
- Niarchos A. P., Gulati O. P., Carretero O. A. Effects of propranolol on the development of renovascular hypertension in the rat. Am Heart J. 1977 Jul;94(1):81–86. doi: 10.1016/s0002-8703(77)80347-5. [DOI] [PubMed] [Google Scholar]
- Ondetti M. A., Rubin B., Cushman D. W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science. 1977 Apr 22;196(4288):441–444. doi: 10.1126/science.191908. [DOI] [PubMed] [Google Scholar]
- Pickering G. Hypertension. Definitions, natural histories and consequences. Am J Med. 1972 May;52(5):570–583. doi: 10.1016/0002-9343(72)90049-6. [DOI] [PubMed] [Google Scholar]
- Rubin B., Antonaccio M. J., Goldberg M. E., Harris D. N., Itkin A. G., Horovitz Z. P., Panasevich R. E., Laffan R. J. Chronic antihypertensive effects of captopril (SQ 14,225), an orally active angiotensin I-converting enzyme inhibitor, in conscious 2-kidney renal hypertensive rats. Eur J Pharmacol. 1978 Oct 15;51(4):377–388. doi: 10.1016/0014-2999(78)90429-6. [DOI] [PubMed] [Google Scholar]
- Rubin B., Laffan R. J., Kotler D. G., O'Keefe E. H., Demaio D. A., Goldberg M. E. SQ 14,225 (D-3-mercapto-2-methylpropanoyl-l-proline), a novel orally active inhibitor of angiotensin I-converting enzyme. J Pharmacol Exp Ther. 1978 Feb;204(2):271–280. [PubMed] [Google Scholar]
- Vollmer R. R., Boccagno J. A. Central cardiovascular effects of SQ 14,225, an angiotensin-converting enzyme inhibitor in chloralose-anesthetized cats. Eur J Pharmacol. 1977 Sep 15;45(2):117–125. doi: 10.1016/0014-2999(77)90081-4. [DOI] [PubMed] [Google Scholar]